411 related articles for article (PubMed ID: 31280451)
1. Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials.
Barbarawi M; Kheiri B; Zayed Y; Gakhal I; Al-Abdouh A; Barbarawi O; Rashdan L; Rizk F; Bachuwa G; Alkotob ML
High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):283-291. PubMed ID: 31280451
[TBL] [Abstract][Full Text] [Related]
2. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis.
Butalia S; Leung AA; Ghali WA; Rabi DM
Cardiovasc Diabetol; 2011 Apr; 10():25. PubMed ID: 21453547
[TBL] [Abstract][Full Text] [Related]
3. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials.
Seidu S; Kunutsor SK; Sesso HD; Gaziano JM; Buring JE; Roncaglioni MC; Khunti K
Cardiovasc Diabetol; 2019 Jun; 18(1):70. PubMed ID: 31159806
[TBL] [Abstract][Full Text] [Related]
4. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.
Sutcliffe P; Connock M; Gurung T; Freeman K; Johnson S; Kandala NB; Grove A; Gurung B; Morrow S; Clarke A
Health Technol Assess; 2013 Sep; 17(43):1-253. PubMed ID: 24074752
[TBL] [Abstract][Full Text] [Related]
5. Benefits and Risks Associated with Low-Dose Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis.
Wang M; Yu H; Li Z; Gong D; Liu X
Am J Cardiovasc Drugs; 2022 Nov; 22(6):657-675. PubMed ID: 35570250
[TBL] [Abstract][Full Text] [Related]
6. Aspirin for Primary Prevention of Cardiovascular Events.
Abdelaziz HK; Saad M; Pothineni NVK; Megaly M; Potluri R; Saleh M; Kon DLC; Roberts DH; Bhatt DL; Aronow HD; Abbott JD; Mehta JL
J Am Coll Cardiol; 2019 Jun; 73(23):2915-2929. PubMed ID: 31196447
[TBL] [Abstract][Full Text] [Related]
7. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups.
Gelbenegger G; Postula M; Pecen L; Halvorsen S; Lesiak M; Schoergenhofer C; Jilma B; Hengstenberg C; Siller-Matula JM
BMC Med; 2019 Nov; 17(1):198. PubMed ID: 31679516
[TBL] [Abstract][Full Text] [Related]
8. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study).
Goicoechea M; de Vinuesa SG; Quiroga B; Verde E; Bernis C; Morales E; Fernández-Juárez G; de Sequera P; Verdalles U; Delgado R; Torres A; Arroyo D; Abad S; Ortiz A; Luño J
Cardiovasc Drugs Ther; 2018 Jun; 32(3):255-263. PubMed ID: 29943364
[TBL] [Abstract][Full Text] [Related]
9. What have we learned about using aspirin for primary prevention from the ASCEND and ARRIVE trials?
Tousoulis D
Cardiovasc Res; 2019 Feb; 115(2):e15-e16. PubMed ID: 30668678
[No Abstract] [Full Text] [Related]
10. Safety and efficacy of aspirin for primary prevention of cancer: a meta-analysis of randomized controlled trials.
Haykal T; Barbarawi M; Zayed Y; Yelangi A; Dhillon H; Goranta S; Kheiri B; Chahine A; Samji V; Kerbage J; Katato K; Bachuwa G
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1795-1809. PubMed ID: 31098750
[TBL] [Abstract][Full Text] [Related]
11. Impact of acetylsalicylic acid on primary prevention of cardiovascular diseases: A meta-analysis of randomized trials.
Upadhaya S; Madala S; Baniya R; Saginala K; Khan J
Eur J Prev Cardiol; 2019 May; 26(7):746-749. PubMed ID: 30861689
[TBL] [Abstract][Full Text] [Related]
12. A Meta-Analysis of Aspirin for the Primary Prevention of Cardiovascular Diseases in the Context of Contemporary Preventive Strategies.
Shah R; Khan B; Latham SB; Khan SA; Rao SV
Am J Med; 2019 Nov; 132(11):1295-1304.e3. PubMed ID: 31153866
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials.
Mahmoud AN; Elgendy AY; Rambarat C; Mahtta D; Elgendy IY; Bavry AA
PLoS One; 2017; 12(4):e0175283. PubMed ID: 28403216
[TBL] [Abstract][Full Text] [Related]
14. Aspirin in the primary prevention of cardiovascular disease on diabetic patients: Systematic review and meta-analysis.
Caldeira D; Alves M; David C; Costa J; Ferreira JJ; Pinto FJ
Prim Care Diabetes; 2020 Jun; 14(3):213-221. PubMed ID: 31791903
[TBL] [Abstract][Full Text] [Related]
15. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.
Berger JS; Krantz MJ; Kittelson JM; Hiatt WR
JAMA; 2009 May; 301(18):1909-19. PubMed ID: 19436018
[TBL] [Abstract][Full Text] [Related]
16. Effect of aspirin on mortality in the primary prevention of cardiovascular disease.
Raju N; Sobieraj-Teague M; Hirsh J; O'Donnell M; Eikelboom J
Am J Med; 2011 Jul; 124(7):621-9. PubMed ID: 21592450
[TBL] [Abstract][Full Text] [Related]
17. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
Berger JS; Roncaglioni MC; Avanzini F; Pangrazzi I; Tognoni G; Brown DL
JAMA; 2006 Jan; 295(3):306-13. PubMed ID: 16418466
[TBL] [Abstract][Full Text] [Related]
18. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials.
Kunutsor SK; Seidu S; Khunti K
Diabet Med; 2017 Mar; 34(3):316-327. PubMed ID: 27086572
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea.
Jung M; Lee S
Drugs Aging; 2020 Jan; 37(1):43-55. PubMed ID: 31755069
[TBL] [Abstract][Full Text] [Related]
20. Acetylsalicylic Acid (Aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Liu S; Eckstein J; Lam A; Cheema AN
Curr Vasc Pharmacol; 2023; 21(2):111-119. PubMed ID: 36718966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
